Loading...
•
Sep 30, 2024
Standard Biotool Q3 2024 Earnings Report
Standard BioTools' financial performance improved with merger synergies and focus on operational efficiency.
Key Takeaways
Standard BioTools reported Q3 2024 revenue of $45 million. The company focused on driving commercial execution and enhancing overall operating efficiency, which led to a 50% adjusted EBITDA improvement and a 35% net loss improvement year-over-year.
Third quarter 2024 revenue was reported as $45 million.
Merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year.
Approximately $80 million in merger synergies were operationalized, expected to be fully realized in 2025.
Cash, cash equivalents, restricted cash and short-term investments totaled $368 million as of September 30, 2024.
Standard Biotool
Standard Biotool
Standard Biotool Revenue by Segment
Revenue by Segment
Instruments Revenue
CapyFin.comConsumables Revenue
CapyFin.com Forward Guidance
The Company has reiterated its full year 2024 revenue guidance to a range of $170 million to $175 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income